Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease | Synapse

November 4, 2017Open Access

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Key Points

Key points are not available for this paper at this time.

Abstract

Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD. (Funded by Otsuka Pharmaceuticals and Otsuka Pharmaceutical Development and Commercialization; REPRISE ClinicalTrials.gov number, NCT02160145 .).

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Torres et al. (Sat,) studied this question.

synapsesocial.com/papers/69e08c5faf805784e5557684 https://doi.org/https://doi.org/10.1056/nejmoa1710030

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial2017 · 179 citations
2Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease2017 · 26 citations
3Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial2017 · 59 citations
4Aging and the Kidneys: Anatomy, Physiology and Consequences for Defining Chronic Kidney Disease2016 · 189 citations
5Unified Criteria for Ultrasonographic Diagnosis of ADPKD2008 · 747 citations